![]() ![]() It is an option to select the law firm to represent the shareholder, but this is not mandatory.įor those who are looking to learn more about the lawsuit, contacting the law firm is an option. This is not necessary for those who want to collect in the event of a monetary return. Shareholders have the option to apply for the lead plaintiff position in the case, but they would need to do this by filing the correct paperwork with the court by May 14, 2014. 'Our partner and aldoxorubicin licensee NantCell has made progress not just for the indications we developed, but also initiating clinical trials testing aldoxorubicin in combination with their immunotherapy protocols in multiple disease states, including metastatic pancreatic cancer, advanced. for future development and commercialization,' said Steven A. Lieff Cabraser Heimann and Bernstein, LLP, filed the class action lawsuit against CytRx in the same court for the aforementioned class period. '2017 was a pivotal year for CytRx with the strategic outlicensing of aldoxorubicin to NantCell, Inc. The law office's website also has an information form that shareholders can fill out and submit.Īnother law office specified that further action was taken against CytRx due to many of the same allegations. The best person to speak with is Darnell Donahue, and he can be reached by telephone or email. Its shares then fell to $4.17, which was $0.61 per share lower.įor those who would like to learn more about the action, it is possible to discuss these matters with the law firm. This occurred due to an article published on, which noted the company's leaders took part in the payment for the articles that artificially improved its stock level. The company had its stock drop again on March 13, 2014. When this information came out, the company's stock declined to $6.04 per share, which was $0.56 per share, or 8.5 percent, lower than the previous level. 12, 2014, a report from noted that the company had an investor relations firm that sent out articles that gave the company positive press while giving author names that did not actually have any involvement in the writing process. On AugCytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, reported financial results for the quarter ended June 30, 2017, and provided an overview of recent accomplishments and plans (Press release, CytRx, AUG 3, 2017, View Source SID1234520029). Shareholders alleged in the suit that the company's leaders violated the Securities Exchange Act of 1934. This includes all shareholders who purchased stock in the company during the class period between Nov. District Court for the Central District of California against CytRx Corporation. Robbins Arroyo, LLP, noted that the litigation was filed in the U.S. A law firm recently alerted shareholders of a biopharmaceutical company that a securities class action lawsuit was filed due to potential federal securities law violations. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |